Clinical Trial Update: An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

An extension Phase 2 study evaluating the safety and tolerability of SEP-363856 in adults with schizophrenia has completed, with results posted in February 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09